MA27001A1 - Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7 - Google Patents

Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7

Info

Publication number
MA27001A1
MA27001A1 MA27310A MA27310A MA27001A1 MA 27001 A1 MA27001 A1 MA 27001A1 MA 27310 A MA27310 A MA 27310A MA 27310 A MA27310 A MA 27310A MA 27001 A1 MA27001 A1 MA 27001A1
Authority
MA
Morocco
Prior art keywords
diesterase
phospho
inhibitors
novel
spirotricyclic
Prior art date
Application number
MA27310A
Other languages
English (en)
Inventor
Edwige Lorthiois
Pierre Ducrot
Fabrice Vergne
Patrick Bernardelli
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27001A1 publication Critical patent/MA27001A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA27310A 2001-03-21 2003-09-12 Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7 MA27001A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/003355 WO2002076953A1 (fr) 2001-03-21 2001-03-21 Nouveaux derives spirotricycliques et utilisation de ces derives en tant qu'inhibiteurs de la phosphodiesterase-7

Publications (1)

Publication Number Publication Date
MA27001A1 true MA27001A1 (fr) 2004-12-20

Family

ID=8164349

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27310A MA27001A1 (fr) 2001-03-21 2003-09-12 Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7

Country Status (46)

Country Link
US (3) US20020198198A1 (fr)
EP (2) EP1373224B1 (fr)
JP (1) JP4086663B2 (fr)
KR (1) KR100617435B1 (fr)
CN (1) CN100447136C (fr)
AP (1) AP1699A (fr)
AR (1) AR033617A1 (fr)
AT (1) ATE367381T1 (fr)
AU (1) AU2002304800B2 (fr)
BG (1) BG108181A (fr)
BR (1) BR0208192A (fr)
CA (1) CA2441313C (fr)
CU (1) CU23218A3 (fr)
CY (1) CY1106829T1 (fr)
CZ (1) CZ20032451A3 (fr)
DE (1) DE60221233T2 (fr)
DK (1) DK1373224T3 (fr)
EA (1) EA006815B1 (fr)
EC (1) ECSP034750A (fr)
EE (1) EE200300459A (fr)
ES (1) ES2288552T3 (fr)
GE (1) GEP20053631B (fr)
GT (1) GT200200053A (fr)
HR (1) HRP20030740A2 (fr)
HU (1) HUP0303637A3 (fr)
IL (2) IL157659A0 (fr)
IS (1) IS2529B (fr)
MA (1) MA27001A1 (fr)
MX (1) MXPA03008485A (fr)
MY (1) MY142045A (fr)
NO (1) NO326086B1 (fr)
NZ (1) NZ527847A (fr)
OA (1) OA12454A (fr)
PA (1) PA8541601A1 (fr)
PE (1) PE20021010A1 (fr)
PL (1) PL367058A1 (fr)
PT (1) PT1373224E (fr)
RS (1) RS50429B (fr)
SI (1) SI1373224T1 (fr)
SK (1) SK11562003A3 (fr)
SV (1) SV2003000925A (fr)
TN (1) TNSN03076A1 (fr)
TW (1) TWI267509B (fr)
UA (1) UA74243C2 (fr)
WO (2) WO2002076953A1 (fr)
ZA (1) ZA200306601B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400244A1 (fr) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
AU2004233863B2 (en) 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
WO2005013997A1 (fr) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Tetrahydroquinazolines spiro-substituees utilisees en tant qu'antagonistes du facteur de liberation de la corticotrophine (crf)
EP2433943B1 (fr) 2004-07-01 2013-09-11 Daiichi Sankyo Company, Limited Intermédiaires pour dérivés de thiénopyrazole ayant une activité inhibitrice de la PDE7
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
US20090111837A1 (en) * 2005-03-01 2009-04-30 Peter Cox Use of pde7 inhibitors for the treatment of neuropathic pain
KR100680497B1 (ko) * 2005-07-25 2007-02-08 엘지전자 주식회사 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
EP1957467A2 (fr) 2005-12-02 2008-08-20 Pfizer Limited Derives spirocycliques
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
EP2068872A1 (fr) * 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008119057A2 (fr) * 2007-03-27 2008-10-02 Omeros Corporation Utilisation d'inhibiteurs pde7 dans le traitement des troubles du
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008142550A2 (fr) * 2007-05-24 2008-11-27 Pfizer Limited Dérivés spirocycliques
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
KR20130124333A (ko) 2010-11-08 2013-11-13 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10479789B2 (en) * 2015-12-16 2019-11-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrido[1,2-A]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107382976A (zh) * 2017-07-04 2017-11-24 孙秀芹 一种治疗盆腔炎的化合物及制备方法和应用
US11685745B2 (en) 2017-07-12 2023-06-27 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021113462A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Dérivés d'un inhibiteur de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352060A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
AU2023326563A1 (en) 2022-08-18 2025-02-27 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815979A (ja) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体およびその製造法
US4764512A (en) 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
WO1994013696A1 (fr) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro-piperidines et homologues favorisant la liberation de l'hormone de croissance
US5602143A (en) * 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
SK45898A3 (en) * 1995-10-17 1999-01-11 Astra Pharma Prod Pharmaceutically active quinazoline compounds
CN1205008A (zh) * 1996-08-30 1999-01-13 协和发酵工业株式会社 咪唑并喹唑啉衍生物
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
CN1179753C (zh) 1999-05-04 2004-12-15 惠氏公司 含有抗孕激素和孕激素的避孕组合物
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
WO2000066560A1 (fr) * 1999-05-04 2000-11-09 American Home Products Corporation Derives de quinazolinone et de benzoxazine tenant lieu de modulateurs du recepteur de progesterone
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
AU2274101A (en) 1999-12-21 2001-07-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
AR033617A1 (es) 2003-12-26
PA8541601A1 (es) 2003-05-14
EE200300459A (et) 2004-02-16
OA12454A (en) 2004-09-30
US20070049558A1 (en) 2007-03-01
WO2002074754A1 (fr) 2002-09-26
IL157659A0 (en) 2004-03-28
HRP20030740A2 (en) 2005-06-30
CA2441313A1 (fr) 2002-09-26
DK1373224T3 (da) 2007-10-15
PE20021010A1 (es) 2003-02-01
CA2441313C (fr) 2009-03-31
CN100447136C (zh) 2008-12-31
PL367058A1 (en) 2005-02-21
ES2288552T3 (es) 2008-01-16
EP1373224B1 (fr) 2007-07-18
GEP20053631B (en) 2005-10-10
NZ527847A (en) 2005-06-24
JP2004529123A (ja) 2004-09-24
US20040214843A1 (en) 2004-10-28
BR0208192A (pt) 2004-03-02
HK1061854A1 (zh) 2004-10-08
NO20034187L (no) 2003-10-15
GT200200053A (es) 2003-02-12
US7214676B2 (en) 2007-05-08
AU2002304800B2 (en) 2007-08-30
SI1373224T1 (sl) 2007-10-31
PT1373224E (pt) 2007-09-25
MY142045A (en) 2010-08-30
IL157659A (en) 2008-08-07
EA006815B1 (ru) 2006-04-28
EP1801106A3 (fr) 2007-07-04
YU74003A (sh) 2006-05-25
KR20030086315A (ko) 2003-11-07
IS6934A (is) 2003-08-29
HUP0303637A2 (hu) 2004-03-01
JP4086663B2 (ja) 2008-05-14
EP1801106A2 (fr) 2007-06-27
SK11562003A3 (sk) 2005-01-03
NO20034187D0 (no) 2003-09-19
ECSP034750A (es) 2003-10-28
EA200300906A1 (ru) 2004-02-26
IS2529B (is) 2009-07-15
BG108181A (bg) 2004-09-30
HUP0303637A3 (en) 2004-07-28
DE60221233T2 (de) 2008-04-03
WO2002076953A1 (fr) 2002-10-03
MXPA03008485A (es) 2003-12-08
AP1699A (en) 2006-12-26
AP2003002857A0 (en) 2003-09-30
UA74243C2 (uk) 2005-11-15
TNSN03076A1 (fr) 2005-12-23
RS50429B (sr) 2009-12-31
CN1498212A (zh) 2004-05-19
DE60221233D1 (de) 2007-08-30
CZ20032451A3 (cs) 2004-09-15
TWI267509B (en) 2006-12-01
ZA200306601B (en) 2004-08-25
NO326086B1 (no) 2008-09-15
CU23218A3 (es) 2007-07-20
US20020198198A1 (en) 2002-12-26
ATE367381T1 (de) 2007-08-15
KR100617435B1 (ko) 2006-08-31
EP1373224A1 (fr) 2004-01-02
SV2003000925A (es) 2003-05-20
CY1106829T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
FR12C0019I2 (fr) O-cyclopropyle-carboxanilides et leur utilisation comme fongicides
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
FR13C0003I2 (fr) Inhibiteurs cycliques de proteine tyrosine kinase
AR028576A1 (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
ATE269327T1 (de) Imidazol-5-yl-2-anilino-pyrimidine als inhibitoren der zellproliferation
PT1370553E (pt) Inibidores de rhoquinase
EP1583997A4 (fr) Elimination de photoresine
MA27230A1 (fr) Derives d'aminoindazoles comme inhibiteurs de proteines-kinase
NO20041293L (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
AR028575A1 (es) Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
CY2012026I2 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf
MA25916A1 (fr) Nouveaux thiadiazoles et oxadiazoles et leur utilisation comme inhibiteurs de la phosphodiesterase-7
EP1534268A4 (fr) Inhibiteurs de la tyrosine kinase
EP1660436A4 (fr) Inhibiteurs de la cathepsine
DZ3357A1 (fr) Nouveaux médicaments composés de dibenzoazulène comme inhibiteurs de facteur onconécrosant
ATE264108T1 (de) Endoparasitizide gelzusammensetzung
AR028068A1 (es) Nuevos derivados de 1,1-dioxotiocromano y su uso como inhibidores de trombina
DZ3367A1 (fr) Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase
DE60031450D1 (de) Polymorph v von torasemid
DE60007360T2 (de) Amorphe modifikation von torasemid
EE200200389A (et) Imidasooli uued derivaadid
AR028075A1 (es) Inhibidores de la peptido-desformilasa